Founded in Culver City, United States, Trace-Ability focuses on manufacturing radiopharmaceuticals for positron-emission tomography (PET) and single-photon emission computed tomography (SPECT). Their core mission is to enhance the quality control of radiotracers through automation and innovation. The company offers products like the Tracer-QC™, an automated solution utilizing optical plate readers, pipetting robots, and single-use consumable kits for release testing of PET and SPECT radiotracers, ensuring optimal cGMP compliance.
Notable figures affiliated with Trace-Ability include their leadership team and a dedicated scientific advisory board. The company has achieved significant milestones in automating radiopharmaceutical quality control, contributing to more reliable and efficient testing processes. Their impact is evident in the improved accuracy and traceability of radiotracer testing, benefiting both the medical imaging industry and patient outcomes.
